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Abstract
Glaucoma is a multifactorial, polygenetic disease with a shared outcome of loss 
of retinal ganglion cells and their axons, which ultimately results in blindness. The 
most common risk factor of this disease is elevated intraocular pressure (IOP), 
although many glaucoma patients have IOPs within the normal physiological range. 
Throughout disease progression, glial cells in the optic nerve head respond to 
glaucomatous changes, resulting in glial scar formation as a reaction to injury. This 
chapter overviews glaucoma as it affects humans and the quest to generate animal 
models of glaucoma so that we can better understand the pathophysiology of this 
disease and develop targeted therapies to slow or reverse glaucomatous damage. 
This chapter then reviews treatment modalities of glaucoma. Revealed herein is 
the lack of non-IOP-related modalities in the treatment of glaucoma. This finding 
supports the use of animal models in understanding the development of glaucoma 
pathophysiology and treatments.
Keywords: animal models, rodents, preclinical models, glaucoma, IOP,  
IOP-lowering, optic nerve degeneration, retinal ganglion cells
1. Introduction
Glaucoma is a heterogenous disease with numerous contributing factors including 
environment, genetics, and epigenetics. It is the primary cause of irreversible blind-
ness in the world and the number of patients diagnosed is only projected to increase in 
the coming years. The use of preclinical animal models has exponentially progressed 
our understanding of the underlying pathophysiology of the disease, as well as provid-
ing a platform for generating and testing successful therapeutics. This chapter delves 
into the fundamentals of glaucoma including the pathologies, types, and symptoms 
with a subsequent description of the numerous preclinical animal models of the 
disease and what has been garnered from their study. We will then discuss treatments 
of glaucoma that are either FDA-approved or in development and conclude by sum-
marizing how pre-clinical studies have advanced the development of new glaucoma 
therapeutics.
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1.1 Basics of glaucoma
The eye is an elaborate structure suited to performing its unique function: 
collecting photons of light and converting that to an electrical signal allowing for 
vision. Because light needs to enter the eye without impedance, the cornea and lens 
lack vasculature. However, a source of nutrients and waste efflux is necessary for 
tissue survival. This necessity is answered by way of the aqueous humor, a water-
based filtrate of the blood produced by the ciliary body of the eye. As it flows from 
the ciliary body through the pupil, the aqueous humor carries and bathes the tissues 
with sugars, vitamins, and other necessary supplies for cellular survival while 
carrying the excreted cellular metabolic waste products back to the blood stream for 
removal. The exit path for the aqueous humor is through the trabecular meshwork, 
Schlemm’s canal and supplementary outflow structures (Figure 1A). Any imbal-
ance between aqueous humor production and its elimination can have an impact on 
intraocular pressure (IOP). As they exit the eye, the axons of retinal ganglion cells 
(RGCs) converge and they become the nerve fibers of the optic nerve (Figure 1B) 
[1]. RGC axon degeneration can be induced by both elevated IOP-related changes 
and IOP-independent factors.
Glaucoma, defined as pathological damage to the optic nerve (ON), results in 
visual field defects due to death of the retinal ganglion cells (RGCs) and damage to 
their axons. Glaucoma is the leading cause of irreversible blindness globally. Trends 
predict that by 2040, as many as 111.8 million people worldwide will have this 
disease [2]. Of the approximately 80 million current cases, 11 million are estimated 
to result in complete blindness [3]. Glaucoma’s primary risk factor is elevated 
intraocular pressure (IOP), although some forms of this disease do not include this 
endophenotype.
This disease is classified into the conventional categories of primary open-
angle glaucoma (POAG) and primary angle-closure glaucoma (PACG), as well as 
primary congenital glaucoma, normotensive glaucoma (NTG), and pigmentary 
dispersion glaucoma. Other rare types exist, such as exfoliation glaucoma and 
traumatic glaucoma. The most important modifiable risk factor for onset and 
progression of glaucoma is elevated IOP, although normotensive glaucoma 
patients suffer from vision loss in spite of their IOP being in the normal physi-
ological range, highlighting the complexity of this disease. In other subtypes of 
Figure 1. 
Aqueous humor dynamics and retinal ganglion cells: two areas of glaucoma-related research. (A) The aqueous 
humor is produced by the ciliary body and exits through the trabecular meshwork and other outflow structures 
leaving the eye and entering the blood stream (flow shown in blue). (B) The axons of the retinal ganglion 
cells (blue) form the optic nerve and run through the lamina cribosa as they exit the eye. In glaucoma, retinal 
ganglion cells and their axons can be damaged due to IOP-related or IOP-independent mechanisms. Figures 
modified from Li, et al. 2012. Courtesy: National Eye Institute, National Institutes of Health.
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this disease, glaucoma can also result from a variety of IOP-related mechanisms 
due to structural alterations that inhibit outflow of aqueous humor. These include 
trabecular meshwork obstruction by foreign material, trabecular endothelial cell 
loss, loss of phagocytic activity of the trabecular meshwork, loss of giant vacuoles 
from the endothelium of Schlemm’s canal and reduced pore size or density in the 
wall of Schlemm’s canal [4].
1.2 Pathophysiology of glaucoma
In the early stages of glaucoma, glial cells in the optic nerve head respond 
to glaucomatous change. IOP-related mechanisms of damage generally include 
obstruction of the trabecular meshwork, morphological changes in astrocytes such 
as enlargement of cell body and processes, as well as upregulation of cytoskeletal 
and extracellular matrix proteins. Studies have demonstrated that remodeling of 
astrocytes and increased deposition of extracellular matrix can occur in some forms 
of experimental glaucoma. Moreover, even a short period of IOP elevation can cause 
hypertrophy, process retraction, and simplification of the shape of astrocytes in 
the optic nerve without changes in gene expression. In addition, the accompany-
ing extracellular matrix deposition is believed to be an early defense mechanism to 
repair or prevent damage to the blood retina barrier [5]. In later stages of glaucoma, 
glial scar formation can occur as a reaction to injury as a method of protection and 
healing. Glial cells recruit immune cells, increasing extracellular matrix deposition 
and inflammatory factors that prevent axonal regeneration [6].
Interestingly, different compartments of RGCs and the optic nerve die by dif-
ferent cellular mechanisms. Specifically, if the RGC axon is cut, the axon distal to 
the lesion degenerates via Wallerian degeneration, while the axon proximal to the 
lesion is removed by a process called dying back. Lastly, the cell body of the axon 
dies via apoptosis [7, 8]. All of which occur among glial scar formation. This process 
of RGC axon loss can be observed in situ during a dilated pupil fundus examination. 
This area of the posterior globe is termed the optic disc with its center termed the 
optic cup. Damage from glaucoma causes destruction of the nerve fibers around the 
rim of this structure and increases the size of the “cup”; an increase in the cup-to-
disc ratio is one of the clinical phenotypes that is used to clinically monitor disease 
progression.
1.3 Classification of glaucoma and early diagnosis in humans
POAG is the most common form of glaucoma and is associated with increased 
IOP [9]. In broad contrast, PACG has a functional trabecular meshwork with 
obstructed access, while the trabecular meshwork in POAG is pathological, but 
open and unobstructed. The initiatory event of PACG is thought to be a blockage 
between the pupillary portion of the iris and the anterior lens surface, which is 
correlated with mid-dilation of the pupil [10]. Primary congenital glaucoma, often 
associated with autosomal recessive disease heritability, results from an abnormal 
development of the anterior segment and angle of the anterior chamber [11]. NTG 
is a disease that is nearly identical to POAG but lacks the increased IOP. Pigmentary 
glaucoma is characterized by accumulation of pigment in the trabecular meshwork 
and corneal endothelium [12].
Because IOP is the only known modifiable risk factor, it is the target of the 
majority of current treatment modalities. Increased age has also demonstrated 
increased risk of ocular hypertension resulting in elevation of IOP and onset 
of POAG [9]. Damage can also ensue from non-IOP-related mechanisms such 
as reduced ocular perfusion pressure, excitotoxicity from excessive glutamate, 
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autoimmune-mediated nerve damage, loss of neurotrophic factors, failure of 
cellular repair mechanisms, and abnormal autoregulation of retinal and choroidal 
vasculature [4]. African-Caribbean descent, near-sightedness, decreased thickness 
of the central cornea, first-degree family history, low ocular perfusion pressure, 
and diabetes are other associated risk factors [13].
The clinical diagnosis of glaucoma relies on recognition of signs of optic 
nerve damage via slit lamp biomicroscopy and examination of the optic nerve 
head, followed by measurement of IOP, assessment of the angle via gonioscope 
and measurement of visual fields. The only directly observable pathology of the 
optic nerve is in the intrascleral portion which can be observed as an increased 
cup-to-disc ratio [14]. Glaucoma can progress over decades if it is not appropri-
ately treated. Because it is not painful unless IOP becomes extremely elevated, 
the early stages of glaucoma often progress undetected. It manifests clinically in 
advanced stages, where it first affects the peripheral vision of the affected eye. 
Unfortunately, the other eye, if unaffected, often compensates for changes in 
the visual field, making most patients unaware of the development and slow loss 
of vision. Early characteristics might be identified as difficulty reading in dim 
light. Due to its asymptomatic and silent onset, assessment of family history and 
frequent clinical assessment is vital. Additionally, assessment of secondary causes 
of IOP elevation can be beneficial in devising a treatment strategy that can include 
medical, laser, and surgical modalities [5].
2. Pre-clinical models of glaucoma
While progress has been made in understanding the genetic pathophysiology of 
glaucoma in humans using genome-wide association studies (GWAS), pre-clinical 
animal models provide an extremely valuable resource for identifying and under-
standing cellular mechanisms of action underlying specific mutations, genetic 
interactions, and ultimately, a knowledge of the disease pathogenesis to better treat 
the condition. They have been used to observe and modify the interplay of genetic 
and environmental factors in complex diseases such as glaucoma. They have also 
been used to develop and evaluate novel therapeutics. This cycle of observation of 
a disease phenotype and therapeutics response in humans, followed by replication 
and in-depth examination in pre-clinical models, with subsequent verification in 
humans, is a bidirectional translation model that is essential to continual forward 
progression of disease and treatment studies (Figure 2). Although there is great 
value to the models that have been created, there remain unmet needs.
There are many factors to consider when selecting an animal species popula-
tion for modeling disease. One is the reproduction of the experimental procedure 
in both the pre-clinical models and humans [15]. For example, in performing an 
electroretinogram (ERG), a measurement of the electrical activity of the retina 
in response to light stimulus, employing the use of anesthetics can affect neuro-
transmission and affect test results [16]. This can become a confounding issue in 
smaller animals which must be anesthetized. Other factors to consider include 
the animal’s body temperature and age. If body temperature decreases enough, 
metabolic processes that affect the chemical reactions necessary for an ERG will 
be decreased, suppressing the amplitude of the ERG, mainly in mice, rats, and 
rabbits due to their body weight to surface area ratio [17]. Age should also be 
considered as it influences amplitudes as well. This has been observed in rabbits 
with younger rabbits exhibiting smaller amplitudes and older rabbits displaying 
larger amplitudes [18]. Obtaining IOP values can also be difficult and the method 
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varies per animal model. In addition, different animal models are susceptible to 
variations from blood pressure, pulse, respiration, anxiety, as well as sedation and 
measurement complications [15].
2.1 Naturally occurring models of primary open angle glaucoma (POAG)
2.1.1 Introduction to naturally occurring animal models of POAG
Many genetic loci containing spontaneous polymorphisms have been identified 
in both human POAG patients and in animals. A few causative genes have been 
identified such as MYOC, OPTN, and WDR36 [11]. Recent studies also postulate 
RGC number is a risk factor with lower numbers found with gene polymorphisms in 
SIX6 (homeobox protein) and ATOH7 (atonal basic helix–loop–helix transcription 
factor 7), both of which are associated with worse outcomes [19–22].
Figure 2. 
The progression of bi-directional translation. (A) A disease phenotype is observed in human patients. (B) The 
observed phenotype is then modeled in a preclinical animal model with as much fidelity to the human condition 
as possible. (C) After rigorous testing in animal models, the outcomes of those tests (pharmaceutical, or other 
therapeutic) are then taken back to the human patients and tested for safety and efficacy. If needed, the process 
repeats. This cycle gives a better comprehension of the disease and how to treat it most effectively.
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2.1.2 POAG in monkeys
Low and high tension POAG was first described in monkeys in 1993. It was 
found to be maternally inherited, and greater than 40% of the models showed 
elevated IOP. They displayed loss of RGCs, degeneration of the optic nerve, and 
damage to the retinal peripheral field. Though while these models are a closer mimic 
to the human condition, they have strong drawbacks including excessive expense, 
care, and more complicated handling procedures [15, 23–25].
2.1.3 POAG in dogs
An autosomal recessive POAG has been studied in beagles. Elevation of IOP was 
seen at 1–2 years of age due to a reduction in aqueous humor outflow. The disease 
was biphasic: early in the disease the iridiocorneal angle was open, followed by 
closure with lens subluxation and displacement from the anterior vitreous patellar 
fossa. The model was used in a genome wide single nucleotide polymorphism array 
study in which the metallopeptidase Adamts10, a candidate gene for POAG, was 
identified. One noteworthy anatomical difference between dogs and humans is that 
dogs have an intrascleral plexus rather than a Schlemm’s canal, which may result in 
minor discrepancies between the two models [11, 15, 26, 27].
2.1.4 POAG in mini-pigs
Mini-pig models have also been used as their retina shows likeness to the human 
retina with holangiotic retinal vasculature, cone photoreceptors in the external 
retina, a similar scleral thickness, and three types of RGCs [28, 29]. This model can 
reproduce IOP elevation and can be used to study ocular regeneration with stem 
cells. Another benefit of this model is its suitability for OCT, corneal topography 
imaging, and ERG analyses [30].
2.1.5 POAG in birds
Avian models of POAG via light induction technique have been described. They 
have shown response to antiglaucoma drugs also, which could be beneficial in drug 
trials targeting IOP [11].
2.1.6 POAG in rodents
Rodent models are valued for their ease of handling and lower management 
costs. They also have a relatively comparable genome to humans. Drawbacks of 
mouse models include the lack of a collagenous lamina cribrosa, although it is 
replaced by one composed of astrocytes. Because the lamina cribrosa is a major 
location of the pathology that causes optic nerve damage, species differences must 
be taken into account [11].
Presently, studies have shown that the mutated human myocilin gene, MYOC 
Tyr437His mutation, causes autosomal dominant severe glaucoma with juvenile 
onset. Mice with a mutation in this same gene develop elevated IOP and 20% RGC 
loss at 18 months, as well as axonal degeneration in the optic nerve and detachment 
of the endothelial cells of the trabecular meshwork [31]. A Col1a1 (alpha-1 subunit 
of collagen type 1) mutation abrogates matrix metalloproteinase-related cleavage, 
necessary for turnover of trabecular meshwork, which leads to aggregation and thus 
increased IOP and RGC death at 24 weeks. This finding infers a correlation between 
IOP regulation and the turnover of fibrillar collagen in the trabecular meshwork [32].
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2.2 Naturally occurring models of PACG
Spontaneous mutations in B10-Sh3pxd2bnee, a rare mutation seen in Frank-ter 
Haar Syndrome, results in glaucoma alongside skeletal and cardiovascular abnor-
malities. The formation of podosomes, which degrade the extracellular matrix, is 
impaired, causing the proliferation of the trabecular meshwork and development 
of iridiocorneal adhesions due to outflow blockage and high IOP resulting in RGC 
loss by 3–4 months in mice harboring the mutation [5]. Spontaneous mutations 
in another gene, the serine protease Prss56, mimic angle-closure glaucoma as the 
ocular axial length is reduced, the lens is large, and thus the angle is narrow [33].
2.3 Primary congenital glaucoma
Congenital glaucoma types include autosomal recessive mutations in CYP1B1 
(cytochrome P450 family 1 subfamily B polypeptide 1) and LTBP2 (Latent-
transforming growth factor beta-binding protein), and autosomal dominant muta-
tions in MYOC (myocilin), OPTN (optineurin), and WDR36 (WD repeat-containing 
protein 36) [5]. Another study adds that the transcription factors FOXC1 (Forkhead 
box C1), FOXC2 (Forkhead box C2), PITX2 (Paired Like Homeodomain 2), LMX1B 
(LIM homeobox transcription factor 1 beta), and PAX6 (Paired box protein)  
contribute to congenital glaucoma [34].
2.3.1 Congenital PACG in rabbits, rats, and cats
Naturally occurring congenital glaucoma was first observed in rabbits in 1886 
[11]. It was also documented in albino New Zealand white rabbits in the 1960s that 
presented with anomalies in the anterior chamber [35–37]. In rats, spontaneous 
congenital glaucoma was seen in 1926 in an inbred family of Wistar-Albino-Glaxo 
rats [38]. This population presents with enlargement of the globe, elevated IOP, 
decreased number of RGCs, and degeneration of the optic nerve head. It has also 
been used in other studies [11]. Feline glaucoma has also been observed with buph-
thalmia and similar phenotypes to human primary congenital glaucoma, though its 
occurrence is rare [39].
2.3.2 Congenital PACG in dogs
Evangelho et al. document that the anatomy of dogs suits the development of 
angle closure because they have reduced ocular axial length, an enlarged lens, and a 
narrow angle [15]. Congenital PACG has been observed in dogs, but it is very rare, 
and has not been used widely for studies of this subtype of glaucoma [11, 40].
2.3.3 Congenital PACG in turkeys
In turkeys, secondary angle closure glaucoma has been observed, presenting 
with buphthalmia, low-grade aqueous cells and flare associated with posterior 
synechiae formation, resulting in pupillary block and iris bombe [41]. It provides a 
functional model for angle closure glaucoma, but it is also rare.
2.4 Pigmentary dispersion glaucoma
Pigmentary dispersion glaucoma, first described in the DBA/2 J mouse in 1978 
presents with a continual increase of IOP until approximately 9 months coupled 
with early onset iris depigmentation. It is caused by spontaneous mutations in 
Animal Models in Medicine and Biology
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tyrosinase-related protein 1 (Tyrp1b) and glycosylated protein nmb (GpnmbR150X) 
[15, 42]. Co-existing mutations in these two genes, leads to pigment dispersion, iris 
atrophy, anterior synechiae, and increased IOP, as well as loss of RGCs and optic 
nerve atrophy that is progressive, even after the IOP returns to lower IOP levels 
in older DBA/2 J mice [43–45]. Similar to humans, it progresses in severity with 
increasing age. Although pigmentary dispersion glaucoma can affect humans, it is 
not linked to mutations in either Tyrp1 or Gpnmb.
2.5 Normotensive glaucoma
Normotensive glaucoma presents with the same characteristics as POAG, but it 
lacks an elevated IOP above the normal physiological range. Speculation concerning 
the mechanism includes lack of blood flow to the optic nerve, vascular spasm, and 
multiple mutations [11]. Recently, some investigators have used the marmoset, a 
small primate, as an experimental glaucoma model. Its advantages include a high 
reproduction rate and a short time to sexual maturation (12–18 months), as well 
as their ease of management and breeding [46]. The transgenic marmoset was 
reported in 2009 as well. Moreover, in 2019 it was documented that aged marmosets 
showed glaucomatous retinal and brain degeneration as well as thinning of the 
lamina cribrosa [46]. They did not have accompanying mutations in glaucoma-
associated genes nor elevation of IOP, which suggest a normotensive glaucoma 
phenotype. It was noted that there was increased oxidative stress and reduced 
brain-derived neurotrophic factor levels, which is neuroprotective for RGCs and 
also reduced in human glaucoma patients [46].
3. Experimentally induced models of glaucoma
To aid in the study of glaucoma-associated optic nerve damage, models have 
been created by directly damaging RGC axons or indirectly through elevation 
of IOP. The optic nerve can be crushed with self-closing fine forceps to cause 
temporally synchronous injury to the RGC axons. This experimental model is 
useful to study the effects of RGC damage, but does not replicate the spontaneous, 
continuous development seen in acute or chronic glaucoma. Kimura et al. advocate 
for experimentally inducible models due to the fact that wild-type animals can be 
used and the experimental condition can be meticulously monitored, as well as the 
progression of disease [46].
3.1 POAG models
IOP can be elevated through direct or indirect blockage of the trabecular mesh-
work via injection of hypertonic saline into episcleral veins, cauterization of the 
episcleral veins, or photocoagulation with an argon laser, which all block outflow 
and induce an elevation of IOP [20].
3.1.1 Laser photocoagulation
Laser photocoagulation has been used as an experimental model in non-human 
primates. This technique damages the trabecular meshwork, which blocks outflow 
of aqueous humor and elevates IOP [47]. It requires three lasers in a 7-day interval 
to increase IOP by 60%. This method is expensive and can cause anterior peripheral 
synechiae, hyphema, and corneal edema. In animals subjected to this procedure, 
it caused loss of RGCs and thinning of the nerve fiber layer, both phenotypes 
9
An Overview of Glaucoma: Bidirectional Translation between Humans and Pre-Clinical…
DOI: http://dx.doi.org/10.5772/intechopen.97145
associated with glaucomatous damage in humans [17, 48]. An argon laser with the 
slit lamp can also be used, but only for certain strains of rodents because it can 
cause pigment affinity and variation in elevation of IOP [49, 50]. If laser photo-
coagulation is combined with temporary narrowing of the iridiocorneal angle via 
paracentesis, this results in a sudden, 3-week increase in IOP that is not reflective of 
glaucoma progression in humans, although more acute changes can be evaluated. 
It can also cause ischemia and opacity of the central cornea [51]. To create a more 
chronic elevation of IOP condition, 50 microliters of hypertonic saline solution 
can be injected into the collecting veins of a rat eye to cause sclerotic damage to 
the trabecular meshwork and optic nerve. This is accomplished with specialized 
microneedles and a complex procedure both difficult to execute and to teach. A 
moderate increase in IOP is seen 7–10 days after the procedure and is recommended 
for use in studies exploring neuroprotection [52]. In addition, a nylon suture can be 
used to occlude the vein and cause an increase in IOP [15, 53].
3.1.2 Glaucoma induced by modifying the trabecular meshwork
Topical application or injection of steroids as IOP modulators has also been 
studied in a variety of animals as a mechanism to elevate IOP and mimic POAG 
[20]. Its mechanism of action is not fully delineated but is believed to function by 
stabilization of the lysosomal membrane and the accumulation of glycosaminogly-
cans polymerized in the trabecular meshwork, which creates resistance to outflow 
of aqueous humor. Outflow resistance is further increased by elevated expression 
of fibronectin, elastin, and laminin, which also hinder outflow [15]. Glaucoma 
induced via this mechanism has been studied in a New Zealand rabbit breed 
[54], which demonstrated that the angle of the anterior chamber is an important 
regulatory mechanism of outflow of aqueous humor. It has been used to further 
understand the composition of the trabecular meshwork, as well as identifying its 
components such as glycosaminoglycans, hyaluronic acid, keratan sulfate, heparan 
sulfate, and sulfate-chondroitin [55, 56].
Based on the increased presence of hyaluronic acid in the trabecular meshwork 
induced by steroids, it was demonstrated that a single application of 1% hyal-
uronic acid in rat models induced an elevation of IOP for up to 8 days, proving 
a useful acute model [15]. Though not well understood, this injection causes an 
accumulation of glycosaminoglycans in the trabecular meshwork, which obstructs 
outflow. This model is noteworthy for its low cost, ease of execution, and sus-
tainability as it induces a more chronic hypertensive state and could be used for 
pharmacological studies [15, 57, 58]. As a candidate for animal models, rats have 
similar benefits to mice. There is a comparable elevation of IOP and corresponding 
optic nerve changes as seen in humans [11]. As such, a second steroidal approach 
involves topical dexamethasone used in rats to elevate IOP and study the regula-
tion of myocilin, previously identified as a causative gene of POAG in humans. 
Though the model demonstrated IOP elevation, mRNA levels of myocilin in the 
trabecular meshwork and in proximity to Schlemm’s canal were not different from 
the control [59].
3.1.3 Reperfusion ischemia
An additional model to mimic open angle glaucoma is via induction of reperfu-
sion ischemia by paracentesis in the anterior chamber. In this method, the can-
nulation of the anterior chamber with a microneedle allows precise control of the 
IOP and suppression of blood flow through the retinal and uveal vasculature. This 
causes IOP-induced damage to the RGCs [15, 47].
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3.2 PACG models
Microspheres have been injected to block the trabecular meshwork and emulate 
PACG. The microspheres do not block the pupil, which allows observation of the 
fundus, which makes this a suitable model. However, fluctuations in IOP can limit 
the efficacy as well as location of the microspheres. Yet, elevation of nitric oxide 
in the aqueous humor was detected in neovascular and angle closure subtypes, 
thought to be due to the inflammatory mechanism. [15, 60]. Bouhenni et al. also 
writes that there are various rat, mice, and rabbit models of PACG to study the 
effects of elevated IOP on RGCs and the optic nerve. These models have been 
created with techniques such as hypertonic saline injection into the episcleral veins, 
cauterization or ligation of the episcleral veins, or laser photocoagulation as dis-
cussed prior [11].
4. Genetically modified models
Genetically modified models allow for a careful examination of the influence 
of typically a single gene mutation on the onset of elevated IOP, RGC damage, and 
the progression of glaucoma. They allow for manipulation of loci that contribute 
to this multifactorial mechanism but require a longer timeframe of study than 
mechanically induced models [15]. An ideal model should be easily reproducible, 
economical, and closely emulate human pathology [15]. Of all the species, the 
mouse is a very common model due to its low cost, ease of breeding and the vast 
genetic resources that are available. Examples of rodent glaucoma models include 
but are not limited to the following: intraocular injection of RGC toxins; crush 
or transection of the ON; manual elevation of IOP using microneedle injection 
into the anterior chamber; laser photocoagulation of the trabecular meshwork or 
episcleral veins; transgenic mice with specific mutations (reviewed in [11, 61]); 
and bead injection into the anterior chamber. While all of these methods have 
merit, none of them completely mimics the array of human disease presentation, 
and therefore additional models of glaucoma are still an unmet need of the vision 
research community.
4.1 POAG models
Transgenic models have been developed such as the bug eye mutant, the lrp2 
(lipoprotein receptor-related protein 2) mutant, and the wdr36 mutant in zebraf-
ish. The bug eye shows RGC death and high IOP and was used to identify lrp2 as 
the gene responsible for the endophenotypes of elevated IOP, large eyes, decreased 
retinal neurons, activation of RGC stress genes, and optic nerve pathology [62–64]. 
Kimura et al. also reports a P2Y6 (pyrimidinergic receptor) knockout (KO) mouse 
that presents with age-dependent optic nerve and RGC degeneration and impaired 
visual function due to excess production of aqueous humor [46].
4.2 PACG models
Vav2/Vav3 (guanine nucleotide exchange factors) KO mice mimic human spon-
taneous development of glaucoma, but there is poor understanding of the patho-
physiology. These models develop buphthalmia and the iridiocorneal angle changes 
before 6 months of age and ultimately chronic angle closure glaucoma occurs [65]. 
They have additionally been identified as candidate genes for a sub-group of open-
angle glaucoma in the Japanese [20]. Bouhenni et al. find three notable features of 
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this model: first, elevated IOP occurs naturally in this model; second, the incidence 
of this phenotype is high and occurs at a reasonably young age; third, human 
hypotensive glaucoma treatments have shown IOP-lowering effects in this model 
[11]. This makes this model useful for targeting molecular mechanisms in develop-
ing understanding of the pathophysiology.
4.3 Primary congenital glaucoma models
Knockout of Foxc1 and Foxc2, genes involved in embryonic and ocular devel-
opment, in mice causes death during the embryonic or neonatal periods [66]. 
Heterozygous Foxc1+/− mice have defects in ocular drainage structures, but do not 
see elevation of IOP. Moreover, Cyp1b1 KO animals develop ocular defects compara-
ble to human congenital glaucoma, presenting with rudimentary Schlemm’s canal, 
abnormalities in the trabecular meshwork, adhesion of the iris to the trabecular 
meshwork and peripheral cornea [15]. Another model was described in an albino 
quail population with a similar phenotype, but due to small size, limited availability, 
and difficult clinical translation, it is rarely used [11].
4.4 Normotensive glaucoma models
Genetically modified mice with normal IOP have been used to further study 
normotensive glaucoma. Specifically, mice lacking the glutamate transporter genes, 
Glast or Eaac1 (Excitatory amino acid transporter 3), develop RGC damage and 
optic nerve degeneration without the IOP elevation. Glast is expressed in Müller 
glia in the retina and aids in the removal of glutamate, sparing RGCs from the 
neuroexcitotoxicity due to its accumulation [46]. Eaac1 is expressed in neurons and 
assists with the uptake of both cysteine and glutamate [46]. This evidence supports 
a protective role of these genes in preventing RGC damage.
A deficiency in apoptosis signal-regulating kinase 1 (Ask1) also known as 
mitogen-activated protein kinase 5 (Map3k5) had no neurotoxic effects or effects 
on IOP. It was also demonstrated that the activation of p38 MAPK and the produc-
tion of inducible nitric oxide synthase was suppressed in glial cells and RGCs, 
implying that ASK1 activation could be involved in normotensive glaucoma 
[67]. Additionally, this model was used to study the neuroprotective effects of 
N-acetylcysteine, which was demonstrated to be protective in the Eaac1 KO mice. 
Kimura et al. also added that Glast or Eaac1 mutations produce an early onset 
phenotype, which increases the utility of this model, particularly in studying effi-
cacy of treatments [46]. This is contrasted with the other models of normotensive 
glaucoma, which are comprised of overexpression of mutated optineurin E50K and 
tank-binding protein 1, the mutated genes associated with human normotensive 
glaucoma [46]. These models have a later onset, which makes them less suitable 
experimentally. In addition, using marmosets mentioned prior, a model is in the 
works targeting the Glast gene, which is speculated to produce a functional model 
with early onset glaucoma [46].
4.5 Immune response models
In the Wallerian degeneration slow (W1dS) mouse, transfection with a fusion 
gene of Nmnat1 and Ube4b protect RGC axons by maintaining mitochondrial func-
tion. An influx of calcium was documented prior to RGC axon degeneration [68, 69]. 
This finding was significant, as it proves there are specific molecular mechanisms 
that modulate axon degeneration. Struebing et. al review other molecular mecha-
nisms of RGC degeneration. For example, knocking out Bax promotes survival of 
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RGC bodies, but does not rescue axons. The JNK (c-Jun, N-terminal kinase) pathway 
is involved in both axonal and soma degradation as deficiency in both Jnk2 and 
Jnk3 results in protection from RGC death after optic nerve crush. Lastly, knocking 
out Dlk (dual leucine zipper kinase) causes cell death in soma but does not affect 
degeneration of axons [20, 70–72].
Within an investigation of an autoimmune response as a plausible mechanism 
of RGC damage, it was determined that serum samples of glaucoma patients 
have increased levels of heat shock protein 27 (HSP27) and heat shock protein 60 
(HSP60). Immunization of these proteins in the Lewis rat population resulted in 
RGC degeneration and axonal loss 1–4 months later, supporting a role of these 
proteins in glaucoma [11, 73].
4.6 The BXD murine family of recombinant inbred lines of mice
Because most human glaucoma cases are not due to polymorphisms in single 
genes, it is not surprising that pre-clinical models that examine the effects of muta-
tions in one gene at a time do not fully recapitulate all endophenotypes of human 
disease. In contrast, a polygenetic approach may advance the field of glaucoma. 
One approach to this is the involvement of the BXD murine family. BXD mice are a 
family of recombinant inbred strains that were derived by mating C57/Bl6 (B6) and 
DBA/2 J (D2) mice and inbreeding the F2 progeny for >20 generations, allowing for 
natural recombination of genes throughout the entire genome.
Each fully inbred BXD strain is genetically distinct and fixed at each locus 
of the genome. This family of mice is an outstanding resource as data on >1000 
phenotypes and nearly 100 expression data sets (gene, protein, and metabolites) 
have been collected and are available on GeneNetwork (www.genenetwork.org), 
an open access resource for the scientific community. Moreover, all BXD and their 
parent strains have been fully sequenced. There are ~5.2 million single nucleotide 
polymorphisms, >400,000 insertions/deletions and multiple copy number variants 
between the progenitors which segregate among the BXD strains. Multiple data sets 
of the eye, retina, optic nerve phenotypes and expression data are also available on 
GeneNetwork to facilitate systems genetics analyses at multiple levels from gene to 
metabolome [74].
The BXD family has become a valuable resource for modeling human disease, 
including glaucoma. B6 has no glaucoma-associated pathologies with fairly constant 
IOP until >13 months of age. The optic nerve has little damage throughout the life 
of B6. In contrast, D2 parents develop pigmentary dispersion glaucoma and have an 
elevated IOP that reaches its maximum at ~9 months with a subsequent IOP reduc-
tion. ON damage increases throughout the lifetime of D2 mice. The influence of 
pigmentary dispersion on glaucoma can be studied among the afflicted progeny or 
be eliminated by excluding those strains that harbor mutations in Tyrp1 and Gpnmb 
from the study plan. By quantifying specific endophenotypes across the BXD family 
along with gene expression and polymorphism profiles, new and informative insights 
regarding novel modulating genes can be revealed. Specific to this pre-clinical murine 
family, several BXD strains spontaneously develop elevated IOP and/or optic nerve 
damage due to the particular set of polymorphisms in the genome of each individual 
strain, similar to the human condition. Importantly, the phenotype of each BXD 
strain is highly reproducible because each strain is fully inbred with a fixed genome 
and the supply of mice from each strain is essentially unlimited.
As a testament to the power of the BXD family and the genetic/genomic infor-
mation gathered from these mice, approximately 20 disease-associated strains have 
already been cloned from the BXD family [74]. One example of the power of using 
BXD mice in the virtuous cycle of bi-directional translation is the identification of 
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the novel IOP-modulating gene, Cacna2d1, which has demonstrated potent IOP-
lowering effects with therapeutic blocking of the function of its gene product with 
pregabalin in a dose-dependent and haplotype-specific manner [74].
In other studies, by examining the immune network and the response of the 
optic nerve to RGC damage, and comparing the two, it was determined that an 
innate immune network was activated by the optic nerve crush [75]. The impor-
tance of the complement cascade or innate immune network as mentioned above, 
has been demonstrated by knocking out C1qa in D2 mice. Both pigmentary disper-
sion glaucoma and elevated IOP are noted, however, the loss of axons in the optic 
nerve is lessened, which points to the role of C1qa in the degeneration of axons in 
the optic nerve [76]. A gene network of regulatory mechanisms in the retina that are 
activated by injury was mapped, and it was determined there are common regula-
tory mechanisms. In addition, there was a significant quantitative trait locus (QTL) 
found on chromosome 16 from 80 to 95 Mb that correlates with the expression of 
C4b in the normal retina [77]. In this region, two cis-acting QTLs were identified as 
potential modulatory genes of the innate immunity network, although the modulat-
ing gene has not yet been identified [20]. These data suggest possible shared disease 
mechanisms with age-related macular degeneration (AMD), in which complement 
proteins are found in the drusen deposits that characterize AMD [45, 78–80].
5. Therapeutics for glaucoma
5.1 Current FDA-approved therapeutics
At baseline, the goal of current glaucoma treatments is to decrease IOP, which is 
presently the only identified modifiable risk factor. There are a variety of medica-
tions that modify IOP by either decreasing production or increasing the outflow 
of aqueous humor. Factors such as patient compliance, costs, drug penetration, 
variations in drug metabolism and bioavailability, and even other factors such 
as systemic diseases, diet, alcohol, etc., all play a role in medical management. 
Additionally, glaucoma patients require long-term treatment to keep pressures low. 
Years of treatment can exacerbate ocular surface disease and cause chronic conjunc-
tival inflammation, which may threaten the efficacy of future surgical procedures 
(such as trabeculectomy). IOP fluctuation can worsen disease progression, seen in 
the advanced glaucoma interventional study [81].
5.1.1 Modulation of aqueous production
Drugs that decrease the production of aqueous, such as beta blockers and 
carbonic anhydrase inhibitors, have been the mainstay in glaucoma treatment for 
years. However, these drugs can have systemic adverse side effects such as brady-
cardia, impotence, exacerbation of asthma, and also may demonstrate tachyphy-
laxis over time. The beta blockers, such as timolol, modulate aqueous inflow. The 
beta-1 receptor increases production of aqueous, and the beta blockers inhibit the 
production of cyclic AMP by this receptor which reduces aqueous production [13]. 
Carbonic anhydrase inhibitors, such as brinzolamide, decrease the production of 
aqueous via suppression of aqueous ducts [13], but can produce a renal metabolic 
acidosis as they inhibit acid secretion in the proximal tubule of the kidney as well 
[13]. Other drugs, such as brimonidine, modulate the production of aqueous via the 
alpha-2 receptor. Adverse effects to this drug can include a delayed hypersensitivity 
reaction and, due to their ability to cross the blood–brain barrier, they are contrain-
dicated in children under two [13].
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5.1.2 Modulation of aqueous humor outflow
Parasympathomimetic drugs, such as pilocarpine, have been used to decrease 
outflow. They cause contraction of the longitudinal ciliary muscles, which increases 
aqueous humor outflow. However, due to its three-to-four times daily dosing para-
digm, myopic shift, and risk of retinal detachment, along with decreased patient 
compliance, it is no longer a first-line treatment [13]. Presently, prostaglandin 
analogs, such as latanoprost (Xalatan), have become the mainstay first-line treat-
ment. They function by increasing outflow via modulation of uveoscleral pores, 
opening them as a secondary outflow mechanism that decreases outflow resistance. 
Most recently, Rho kinase inhibitors, such as Rhopressa, inhibit actin/myosin 
contraction of these muscles and improve trabecular meshwork outflow by decreas-
ing the episcleral venous pressure. In the acute setting, hyperosmotic agents such as 
glycerol and mannitol can be used to lower the IOP, given intravenously, increasing 
the tonicity of the plasma and drawing aqueous out of the eye [13].
5.1.3 Sustained-release devices
To combat challenges of drug delivery, different models of sustained release 
implants have been developed. One intracameral implant called Durysta is an FDA-
approved device that delivers bimatoprost into the anterior chamber over a period 
of four months [82]. Unfortunately, complications of Durysta use include chronic 
inflammation and corneal endothelial cell loss.
Other sustained-release implants in development include intracanalicular 
devices, subconjunctival injections, and collagen shields [83]. Examples include 
latanoprost micro-dose delivery with Optejet (Microprost, Eyenovia), latano-
prost delivery via an intracanalicular insert (OTX-TIC, Ocular Therapeutix), and 
latanoprost or travoprost delivery via a punctal plug (L-evolute and T-evolute, 
Mati Therapeutics). The latter includes two travoprost delivery platforms, ENV515 
(Envisia Therapeutics) and iDose (Glaukos) [83–85]. iDose is a titanium implant 
that releases a unique formulation of travoprost into the anterior chamber [84]. It 
releases micro-amounts of the drug over a year and eliminates the barrier of the 
cornea. It is composed of three parts that titrates travoprost release [84, 86]. It was 
reported in a randomized, double-blind phase II trial, iDose achieved a 30% reduc-
tion in IOP at 12 months, lowering the average number of glaucoma medications 
per patient compared to the control group of 0.5% timolol, demonstrating non-
inferiority with minimal adverse effects [84]. At each stage of development of these 
FDA-approved therapeutics, multiple pre-clinical models were used to demonstrate 
safety and efficacy, making their inclusion in the drug pipeline invaluable.
5.2 Therapeutics in development
Treatments that mitigate risk factors other than IOP are an identified gap in 
treatment modalities [46]. These are especially needed for populations that do not 
respond to current IOP-lowering medications, when a lowered IOP is insufficient to 
halt visual field loss, and in normotensive glaucoma cases. A particular need exists 
for the identification of neuroprotective molecules that act directly on the optic nerve 
and RGC axons. Although several therapies are being evaluated in multiple labo-
ratories across the world, there remains no FDA-approved neuroprotective option 
for glaucoma patients. In line with this treatment strategy, Kimura et al. disclosed 
treatment trials exploring the delivery of ciliary neurotrophic factor into the eye via 
modified human cells that secrete it. They postulate this mechanism has potential for 
neuroprotective effects in the treatment of normotensive glaucoma [46]. In addition, 
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on the progressive end of molecular modifying, it may be possible to use stem cell 
therapy with CRISPR-Cas 9 technology to neutralize mutations causing glaucoma 
phenotypes. This capability is currently being explored [15], but will take thoughtful 
risk/benefit analysis.
Approaching treatment from a different angle, a unique tool to modulate IOP is 
being explored. The Mercury Multi-Pressure Dial (Equinox) is a pair of pressurized 
goggles that create a pressure vacuum around the eye, which decreases pressure 
from gravity and increases ocular blood flow [87]. They operate on the principal 
that glaucoma is likely a dual-pressure disease due to the balance between IOP and 
intracranial pressure (ICP) [87]. Thus, the inventors of this device postulate that 
glaucoma is a result of high IOP and low ICP. By applying a moderate negative pres-
sure in the front of the eye with their goggles, the pressure inside the eye is reduced 
and the ICP is restored to a physiological level [87]. Moreover, it serves as a point to 
demonstrate that one direction glaucoma treatment might be headed is 24/7 modu-
lation of pressure where sensors monitor pressure on-the-go, allowing physicians 
access to IOP data without requiring an office visit and creating a practical opportu-
nity for a telemedicine consultation.
Experimental models of glaucoma are crucial to understanding the mechanism 
of disease and designing novel treatments. Assessing their axonal degeneration 
in optic nerve cross sections has proven beneficial in this pursuit. Specifically, the 
BXD genetic reference panel will be used to detect and study spontaneous models 
of glaucoma. This will be invaluable to the scientific community, especially in an 
effort to develop novel treatment options. While the development of these novel 
modalities takes time, animal models can be used to explore the benefit of existing 
drugs, a method known as drug repositioning or repurposing [67]. Neuroprotection 
is one particular facet of interest, and it is postulated available drug modalities for 
diseases of the central nervous system such as Alzheimer’s or Parkinson’s might also 
exhibit neuroprotection in glaucoma patients [88]. Examples of these trials include 
memantine, valproic acid, edaravone, and niacin (vitamin B3). Unfortunately, 
memantine was ruled ineffective in 2018 [89]. Valproic acid was demonstrated to be 
neuroprotective in rodent models of normotensive glaucoma, and one study from 
India showed improvement of advanced glaucoma cases [90, 91]. Edaravone was 
also shown to decrease RGC death in mouse models of normotensive glaucoma [92]. 
Lastly, oral niacin was demonstrated to be protective in mouse models [93]. There 
is also interest in the potential of dairy products being neuroprotective due to their 
levels of spermidine, which is a compound that has demonstrated neuroprotection 
in mouse models [67]. Additionally, using rodent models, Chintalapudi et al. have 
demonstrated IOP-lowering effects of pregabalin, which inhibits calcium channels 
containing the CACNA2D1 subunit. It is mainly used for neuropathic pain but was 
developed initially as an antiepileptic [74, 94]. Animal models have clearly demon-
strated their necessity in testing for current and future pharmacological treatments.
6.  Bidirectional translation from humans to pre-clinical models and 
back again
The virtuous cycle of bidirectional translation works through the observation of 
disease phenotypes and processes in human patients, followed by replication and 
examination of the specific observation in normal and pathological pre-clinical 
models to discover novel modulators of complex disease mechanisms, and ulti-
mately test those outcomes back in human patients. This process should be repeated 
until a safe and effective treatment paradigm is obtained or the disease process of 
better understood. This strategy clearly supports the hypothesis that breakthroughs 
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in human and experimental models fuel a sustainable model of human observation, 
pre-clinical model experimentation, and verification in humans. As direct support 
for this strategy, as discussed above, with the known observation that elevated IOP 
is the chief modifiable risk factor for POAG, Chintalapudi et al. used strains from 
the BXD family of mice and identified a novel gene modulator of IOP—calcium 
voltage-gated channel auxiliary subunit alpha2delta 1 (Cacna2d1)— that was 
confirmed in human GWAS investigations [74]. These findings were the platform 
that allowed for the discovery of pregabalin, an inhibitor of CACNA2D1, as a new 
IOP-lowering drug with a novel mechanism of action [74]. This, as well as the 
variety of molecular models discussed above, demonstrates the efficacy of bidirec-
tional translation in driving the diagnosis, treatment, and prevention of complex 
diseases [95].
The collective generation of large datasets like GWAS have facilitated the identi-
fication of gene modulators of complex traits and disease mechanisms. Those tools 
alone, however, do not account for the complex interplay between inherited and 
environmental factors. Human limitations are clear; animal models are equipped 
with the biological resources to support the detailed analyses of disease progression. 
Pre-clinical models reveal instrumental pathophysiology, which when translated to 
humans, fuels the evolution of molecular, cellular, developmental, and physiologi-
cal research [95]. However, glaucoma is a multifaceted disease, which one animal 
model alone cannot flawlessly emulate. Different animal models display unique 
features of the pathophysiology of the disease and each help further understanding 
of glaucoma progression as a whole.
7. Conclusion
In conclusion, the future of glaucoma treatment is in understanding disease 
mechanisms of glaucoma viewed with an interventional mindset. Increasingly, 
the safety and efficacy of drug delivery allows better control of IOP. Medical 
management shortly seeks to improve sustainability through products like Durysta 
and iDose. Innovation of medical management is in progress with formulations 
of N-acetylcysteine or ciliary neurotrophic factor, as mentioned. It is speculated 
that glaucoma is headed in a direction of earlier detection, earlier intervention, 
and chronic modulation, potentially even with tools to adequately assess pressure 
from home (even 24/7), and to address it with telehealth resources. Technology 
may permit detection of resistance sites, which allows specification of procedures 
specific to the individual patient. Largely, it is evident that there is a gap in the 
treatment of glaucoma with non-IOP-related modalities. This supports the need 
for animal models in developing further understanding of the pathophysiology of 
glaucoma, but also in studying the efficacy of present treatment mechanisms (such 
as IOP-lowering) as well as novel ones (N-acetylcysteine, ciliary neurotrophic factor, 
molecular mapping with animal models, CRISPR-CAS9).
Something to consider with the current information-driven culture, are 
mechanisms to objectively quantify the degree of pathophysiology present in 
these animal models, particularly when they are used to examine the efficacy of 
treatment modalities. Currently, a particular BXD strain which spontaneously 
develops glaucoma is being used to observe optic nerve pathology (including axonal 
degeneration and glial scarring) and objectively quantify glaucomatous degenera-
tion. This, as well as the potential of an automated system to carry out this task, 
has the ability to revolutionize this field. A deep neural network is being developed 
to reliably assess the progression of axonal degeneration in glaucoma. It provides 
an opportunity to automate this process to better understand the mechanism of 
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glaucoma—etiologically and clinically—and to assess the efficacy of treatment 
trials. By using a uniform stratification of disease progression, large volume stud-
ies can be conducted with greater precision, efficiency, and less bias. This will 
allow for exponential growth in the understanding and treatment of glaucoma as 
the knowledge of pathophysiology is enhanced. It showcases the use of artificial 
intelligence to autonomously convert subjective data to an objective form of precise 
stratification.
To summarize, this chapter makes one thing clear. The “virtuous cycle” of bidi-
rectional translation is essential to further understanding of the pathophysiology of 
glaucoma. It is the common tool necessary to further observe disease advancement, 
design more molecular models, identify disease modulators, and discover new 
therapeutics. Moreover, this chapter reveals that pre-clinical models illuminate this 
path forward.
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